Interactions Between Tumor-derived Proteins and Toll-like Receptors

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2020 Dec 10

PMID 33299138

Citations 43

Authors

Gun-Young Jang

Ji Won Lee

Young Seob Kim

Sung Eun Lee

Hee Dong Han

Kee-Jong Hong

Tae Heung Kang

Yeong-Min Park

Affiliations

Soon will be listed here.

Abstract

Damage-associated molecular patterns (DAMPs) are danger signals (or alarmins) alerting immune cells through pattern recognition receptors (PRRs) to begin defense activity. Moreover, DAMPs are host biomolecules that can initiate a noninflammatory response to infection, and pathogen-associated molecular pattern (PAMPs) perpetuate the inflammatory response to infection. Many DAMPs are proteins that have defined intracellular functions and are released from dying cells after tissue injury or chemo-/radiotherapy. In the tumor microenvironment, DAMPs can be ligands for Toll-like receptors (TLRs) expressed on immune cells and induce cytokine production and T-cell activation. Moreover, DAMPs released from tumor cells can directly activate tumor-expressed TLRs that induce chemoresistance, migration, invasion, and metastasis. Furthermore, DAMP-induced chronic inflammation in the tumor microenvironment causes an increase in immunosuppressive populations, such as M2 macrophages, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs). Therefore, regulation of DAMP proteins can reduce excessive inflammation to create an immunogenic tumor microenvironment. Here, we review tumor-derived DAMP proteins as ligands of TLRs and discuss their association with immune cells, tumors, and the composition of the tumor microenvironment.

Citing Articles

NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance.

Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L Front Immunol. 2025; 16:1518664.

PMID: 39949765 PMC: 11821961. DOI: 10.3389/fimmu.2025.1518664.

Dengue virus infection: how platelet-leukocyte crosstalk shapes thrombotic events and inflammation.

Amin A, Nikdoust F, Khorram S, Marashi S, Ghanavati P, Ameri F Mol Biol Rep. 2025; 52(1):119.

PMID: 39804486 DOI: 10.1007/s11033-025-10222-x.

CD38 Coordinates with NF-κB to Promote Cochlear Inflammation in Noise-Induced Hearing Loss: the Protective Effect of Apigenin.

Liu D, Sai N, Zhou Y, Yu N, Jiang Q, Sun W Mol Neurobiol. 2024; .

PMID: 39725836 DOI: 10.1007/s12035-024-04675-7.

Differential Expression of Neurodegeneration-Related Genes in SH-SY5Y Neuroblastoma Cells Under the Influence of Cyclophilin A: Could the Enzyme be a Likely Trigger and Therapeutic Target for Alzheimer's Disease?.

Pashaei S, Shabani S, Mohammadi S, Morozova-Roche L, Salari N, Rahimi Z Neurochem Res. 2024; 50(1):47.

PMID: 39636462 DOI: 10.1007/s11064-024-04253-2.

Pancreatic Adenocarcinoma Up-Regulated Factor (PAUF) Transforms Human Monocytes into Alternative M2 Macrophages with Immunosuppressive Action.

Kim Y, Nanda S, Jiang F, Pyo S, Han J, Koh S Int J Mol Sci. 2024; 25(21).

PMID: 39519098 PMC: 11547018. DOI: 10.3390/ijms252111545.

References

Srikrishna G, Freeze H . Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009; 11(7):615-28. PMC: 2697348. DOI: 10.1593/neo.09284. View

Schirrmacher V, Fournier P . Danger signals in tumor cells: a risk factor for autoimmune disease?. Expert Rev Vaccines. 2010; 9(4):347-50. DOI: 10.1586/erv.10.15. View

Patidar A, Selvaraj S, Sarode A, Chauhan P, Chattopadhyay D, Saha B . DAMP-TLR-cytokine axis dictates the fate of tumor. Cytokine. 2017; 104:114-123. DOI: 10.1016/j.cyto.2017.10.004. View

Zhang J, Shao S, Han D, Xu Y, Jiao D, Wu J . High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway. Int J Oncol. 2018; 53(2):659-671. PMC: 6017266. DOI: 10.3892/ijo.2018.4420. View

Choi C, Kang T, Song J, Kim Y, Chung E, Ylaya K . Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. Sci Rep. 2018; 8(1):12161. PMC: 6093878. DOI: 10.1038/s41598-018-30582-8. View

Park H, Lee Y, Oh Y, Jung J, Park Y, Myung K . Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene. 2010; 30(2):201-11. PMC: 3399130. DOI: 10.1038/onc.2010.401. View

Harris H, Andersson U . Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004; 34(6):1503-12. DOI: 10.1002/eji.200424916. View

Krysko D, Agostinis P, Krysko O, Garg A, Bachert C, Lambrecht B . Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011; 32(4):157-64. DOI: 10.1016/j.it.2011.01.005. View

10.

Kaczmarek A, Vandenabeele P, Krysko D . Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013; 38(2):209-23. DOI: 10.1016/j.immuni.2013.02.003. View

11.

Nace G, Evankovich J, Eid R, Tsung A . Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2011; 4(1):6-15. DOI: 10.1159/000334245. View

12.

Breugom A, Swets M, Bosset J, Collette L, Sainato A, Cionini L . Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015; 16(2):200-7. DOI: 10.1016/S1470-2045(14)71199-4. View

13.

Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D . Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002; 95(1):155-63. DOI: 10.1002/cncr.10630. View

14.

Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M . Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011; 30(1):61-9. DOI: 10.1007/s10555-011-9273-4. View

15.

Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G . How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev. 2011; 30(1):71-82. DOI: 10.1007/s10555-011-9283-2. View

16.

Im K, Nam Y, Kim N, Song Y, Lee E, Lim J . Regulation of HMGB1 release protects chemoradiotherapy-associated mucositis. Mucosal Immunol. 2019; 12(5):1070-1081. DOI: 10.1038/s41385-019-0132-x. View

17.

Sims G, Rowe D, Rietdijk S, Herbst R, Coyle A . HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010; 28:367-88. DOI: 10.1146/annurev.immunol.021908.132603. View

18.

Tang D, Kang R, Zeh 3rd H, Lotze M . High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799(1-2):131-40. PMC: 2818552. DOI: 10.1016/j.bbagrm.2009.11.014. View

19.

Wang H, Yang H, Tracey K . Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004; 255(3):320-31. DOI: 10.1111/j.1365-2796.2003.01302.x. View

20.

Tsung A, Sahai R, Tanaka H, Nakao A, Fink M, Lotze M . The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005; 201(7):1135-43. PMC: 2213120. DOI: 10.1084/jem.20042614. View

21.

Andersson U, Erlandsson-Harris H . HMGB1 is a potent trigger of arthritis. J Intern Med. 2004; 255(3):344-50. DOI: 10.1111/j.1365-2796.2003.01303.x. View